{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-003859","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.620580+00:00","generated_at":"2026-06-17T09:50:58.897442+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","bullets":["Nasdaq notified Tenax on March 29, 2023 that bid price closed below $1.00 for 30 consecutive business days.","Company has until September 25, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, Company may be eligible for additional 180-day period if it meets other listing standards.","No immediate effect on listing; stock continues trading under TENX on Nasdaq Capital Market.","Company evaluating options including potential reverse stock split to cure deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-003859","json":"https://secwatch.observer/filing/0001654954-23-003859.json","markdown":"https://secwatch.observer/filing/0001654954-23-003859.md","text":"https://secwatch.observer/filing/0001654954-23-003859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423003859/0001654954-23-003859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423003859/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:50:58.897442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"787be93ee66997da7bc6853dc3a472f769504174","claim":"TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 29, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Tenax Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until September 25, 2023, to regain compliance with the Bid Price Rule. If at any time before September 25, 2023","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423003859/0001654954-23-003859-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}